Cancer Turns 75 von Ramalingam, Suresh S.

Volltext

Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions von Marullo, Rossella, Werner, Erica, Degtyareva, Natalya, Moore, Bryn, Altavilla, Giuseppe, Ramalingam, Suresh S, Doetsch, Paul W

Volltext

Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? von Steuer, Conor E, Ramalingam, Suresh S

Volltext

Cancer matters: Now more than ever von Ramalingam, Suresh S.

Volltext

The MARIPOSA trials — implications for the treatment of EGFR-mutant NSCLC von Ardeshir-Larijani, Fatemeh, Ramalingam, Suresh S.

Volltext

Lung cancer: New biological insights and recent therapeutic advances von Ramalingam, Suresh S., Owonikoko, Taofeek K., Khuri, Fadlo R.

Volltext

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer von Ramalingam, Suresh S, Yang, James C-H, Lee, Chee Khoon, Kurata, Takayasu, Kim, Dong-Wan, John, Thomas, Nogami, Naoyuki, Ohe, Yuichiro, Mann, Helen, Rukazenkov, Yuri, Ghiorghiu, Serban, Stetson, Daniel, Markovets, Aleksandra, Barrett, J Carl, Thress, Kenneth S, Jänne, Pasi A

Volltext

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature von Pillai, Rathi N., Behera, Madhusmita, Owonikoko, Taofeek K., Kamphorst, Alice O., Pakkala, Suchita, Belani, Chandra P., Khuri, Fadlo R., Ahmed, Rafi, Ramalingam, Suresh S.

Volltext

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers von Ready, Neal, Hellmann, Matthew D, Awad, Mark M, Otterson, Gregory A, Gutierrez, Martin, Gainor, Justin F, Borghaei, Hossein, Jolivet, Jacques, Horn, Leora, Mates, Mihaela, Brahmer, Julie, Rabinowitz, Ian, Reddy, Pavan S, Chesney, Jason, Orcutt, James, Spigel, David R, Reck, Martin, O'Byrne, Kenneth John, Paz-Ares, Luis, Hu, Wenhua, Zerba, Kim, Li, Xuemei, Lestini, Brian, Geese, William J, Szustakowski, Joseph D, Green, George, Chang, Han, Ramalingam, Suresh S

Volltext

CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions von Hashimoto, Masao, Kamphorst, Alice O, Im, Se Jin, Kissick, Haydn T, Pillai, Rathi N, Ramalingam, Suresh S, Araki, Koichi, Ahmed, Rafi

Volltext

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset von Ohe, Yuichiro, Imamura, Fumio, Nogami, Naoyuki, Okamoto, Isamu, Kurata, Takayasu, Kato, Terufumi, Sugawara, Shunichi, Ramalingam, Suresh S, Uchida, Hirohiko, Hodge, Rachel, Vowler, Sarah L, Walding, Andrew, Nakagawa, Kazuhiko

Volltext

Personalized therapy for lung cancer: striking a moving target von Pakkala, Suchita, Ramalingam, Suresh S

Volltext

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer von Jänne, Pasi A, Yang, James Chih-Hsin, Kim, Dong-Wan, Planchard, David, Ohe, Yuichiro, Ramalingam, Suresh S, Ahn, Myung-Ju, Kim, Sang-We, Su, Wu-Chou, Horn, Leora, Haggstrom, Daniel, Felip, Enriqueta, Kim, Joo-Hang, Frewer, Paul, Cantarini, Mireille, Brown, Kathryn H, Dickinson, Paul A, Ghiorghiu, Serban, Ranson, Malcolm

Volltext

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden von Hellmann, Matthew D, Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory A, Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S, Brahmer, Julie, Reck, Martin, O’Byrne, Kenneth J, Geese, William J, Green, George, Chang, Han, Szustakowski, Joseph, Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, Paz-Ares, Luis

Volltext

Systemic Chemotherapy for Advanced Non‐Small Cell Lung Cancer: Recent Advances and Future Directions von Ramalingam, Suresh, Belani, Chandra

Volltext

Immune checkpoint inhibitors in advanced non–small cell lung cancer von Assi, Hazem I., Kamphorst, Alice O., Moukalled, Nour M., Ramalingam, Suresh S.

Volltext

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component von Yang, James Chih-Hsin, Ahn, Myung-Ju, Kim, Dong-Wan, Ramalingam, Suresh S, Sequist, Lecia V, Su, Wu-Chou, Kim, Sang-We, Kim, Joo-Hang, Planchard, David, Felip, Enriqueta, Blackhall, Fiona, Haggstrom, Daniel, Yoh, Kiyotaka, Novello, Silvia, Gold, Kathryn, Hirashima, Tomonori, Lin, Chia-Chi, Mann, Helen, Cantarini, Mireille, Ghiorghiu, Serban, Jänne, Pasi A

Volltext

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer von Reungwetwattana, Thanyanan, Nakagawa, Kazuhiko, Cho, Byoung Chul, Cobo, Manuel, Cho, Eun Kyung, Bertolini, Alessandro, Bohnet, Sabine, Zhou, Caicun, Lee, Ki Hyeong, Nogami, Naoyuki, Okamoto, Isamu, Leighl, Natasha, Hodge, Rachel, McKeown, Astrid, Brown, Andrew P, Rukazenkov, Yuri, Ramalingam, Suresh S, Vansteenkiste, Johan

Volltext

Sotorasib for Lung Cancers with KRAS p.G12C Mutation von Skoulidis, Ferdinandos, Li, Bob T, Dy, Grace K, Price, Timothy J, Falchook, Gerald S, Wolf, Jürgen, Italiano, Antoine, Schuler, Martin, Borghaei, Hossein, Barlesi, Fabrice, Kato, Terufumi, Curioni-Fontecedro, Alessandra, Sacher, Adrian, Spira, Alexander, Ramalingam, Suresh S, Takahashi, Toshiaki, Besse, Benjamin, Anderson, Abraham, Ang, Agnes, Tran, Qui, Mather, Omar, Henary, Haby, Ngarmchamnanrith, Gataree, Friberg, Gregory, Velcheti, Vamsidhar, Govindan, Ramaswamy

Volltext

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor–mutant lung cancers von Gu, Jiajia, Yao, Weilong, Shi, Puyu, Zhang, Guojing, Owonikoko, Taofeek K., Ramalingam, Suresh S., Sun, Shi‐Yong

Volltext